Advertisement

Topics

Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)

2014-07-23 21:12:24 | BioPortfolio

Summary

To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.

Description

All the patients whom an investigator prescribes the first Azithromycin SR should be registered within 14 days.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Conditions

Bacterial Infections

Intervention

Azithromycin SR

Status

Enrolling by invitation

Source

Pfizer

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:12:24-0400

Clinical Trials [895 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin pl...

A Study of Azithromycin in HIV-Infected Patients

To assess the dose proportionality of azithromycin concentrations and toleration when delivered in tablet formulation to HIV-infected patients. The need exists to further assess the antib...

Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

Outpatient Registry Trial of Respiratory Tract Infections in Adults

To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

The objectives of the study were to confirm that a single, 2.0-g dose of azithromycin sustained release (SR) was at least as effective to 10 days of oral levofloxacin 500 mg once a day, wh...

PubMed Articles [6482 Associated PubMed Articles listed on BioPortfolio]

Long-term Impact of Oral Azithromycin taken by Gambian women during Labour on Prevalence and Antibiotic Susceptibility of S. pneumoniae and S. aureus in their Infants: Follow up of a Randomized Clinical Trial.

Oral azithromycin given to women in labour decreases maternal and neonatal bacterial carriage but increases azithromycin resistant bacteria during at least 4 weeks following the intervention. We asses...

Prevalence of Mycoplasma genitalium and Azithromycin-Resistant Infections Among Remnant Clinical Specimens, Los Angeles.

Mycoplasma genitalium is an important cause of bacterial sexually transmitted diseases. Diagnosis and susceptibility testing of Mycoplasma genitalium are limited by the fastidious nature of the organi...

Invasive Bacterial Infections in Infants Younger Than 60 Days With Skin and Soft Tissue Infections.

The objective of this study was to describe the frequency of invasive bacterial infections (IBIs) in young infants with skin and soft tissue infections (SSTIs) and the impact of IBI evaluation on disp...

Both localized and systemic bacterial infections are predicted by injection drug use: A prospective follow-up study in Swedish criminal justice clients.

Both skin and soft tissue infections (SSTI) and systemic bacterial infections are common in people who inject drugs (PWID), but data on incidence and risk factors are lacking. We compared registered d...

Early target attainment of azithromycin therapy in children with lower respiratory tract infections.

Early target attainment is the key factor influencing the outcome of antimicrobial therapy. The objective of the present study was to evaluate the relationship between azithromycin concentrations duri...

Medical and Biotech [MESH] Definitions

Bacterial infections of the brain, spinal cord, and meninges, including infections involving the perimeningeal spaces.

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process.

Inflammation of the lung parenchyma that is caused by bacterial infections.

Infections by bacteria, general or unspecified.

More From BioPortfolio on "Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial